NCT01662674已完成1 期
A Randomized, Open-label, Oral Single Dosing, Two-way Crossover Clinical Trial to Compare the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered in Healthy Male Volunteers
LG Life Sciences1 个研究点 分布在 1 个国家目标入组 27 人开始时间: 2012年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 27
- 试验地点
- 1
- 主要终点
- AUClast
研究概览
简要总结
This study is to evaluate the safety/tolerability and pharmacokinetics/pharmacodynamics of the combinations of gemigliptin 50mg and metformin HCl extended release 1000mg in comparison to each component administered in healthy male volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Age between 20 to 45, healthy male subjects(at screening)
- •Body weight between 55kg - 90kg, BMI between 18.0 - 27.0
- •FPG 70-125mg/dL glucose level(at screening)
- •Subject who totally understand the progress of this clinical trials, make decision by his free will, and signed a consent form to follow the progress.
排除标准
- •Subject who has past or present history of any diseases following below.(liver including hepatitis virus carrier, kidney, Neurology,immunology,pulmonary,endocrine,hematooncology,cardiology,mental disorder.)
- •Subject who had GI tract disease or(ulcer, acute or chronic pancreatitis) surgery.(appendectomy, hernioplasty are not included)
- •Subject who had drug hypersensitivity reaction.(Aspirin, antibiotics)
- •Subject who already participated in other trials in 3months
- •Subject who had whole blood donation in 2months, or component blood donation in 1months or transfusion in 1months currently.
- •Smokers.(but, if the subject did'nt smoke in 3months, can participate the trial)
研究组 & 干预措施
G+M
Experimental
Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg
干预措施: gemigliptin and metformin HCl extended release (Drug)
C
Experimental
Combination of gemigliptin50mg/metformin HCl extended release 1000mg
干预措施: gemigliptin/metformin HCl extended release (Drug)
结局指标
主要结局
AUClast
时间窗: up to 48h post-dose
To evaluate AUClast of gemigliptin and metformin
Cmax
时间窗: up to 48h post-dose
To evaluate Cmax of gemigliptin and metformin
次要结局
- AUEC(up to 48h post-dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
BE Study of the Combinations of Gemigliptin/Metformin HCl Extended Release 50/1000mg(25/500mg x 2 Tablets) in Comparison to Each Component Administered AloneHealthy Male VolunteersNCT03355014LG Chem70
已完成
1 期
A Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Combination of Rosuvastatin and CS-866 and DWJ1276Healthy VolunteersNCT01493856Daewoong Pharmaceutical Co. LTD.58
Unknown
1 期
Study of DWJ1351 in Healthy Male VolunteersHealthyNCT02665832Daewoong Pharmaceutical Co. LTD.58
已完成
1 期
To Evaluate the Pharmacokinetic Characteristics and Safety in Healthy VolunteersHealthyNCT06361277JW Pharmaceutical56
已完成
1 期
Phase 1 Clinical Trial to Investigate the Effect on the Pharmacokinetics of YH14755 Compared to Co-administration of Rosuvastatin and Metformin SR in Healthy VolunteersHealthyNCT02125227Yuhan Corporation56